Jump to Main Content
Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi‐institutional retrospective study of 64 cases
- Evans, B. J., O'Brien, D., Allstadt, S. D., Gregor, T. P., Sorenmo, K. U.
- Veterinary and comparative oncology 2018 v.16 no.1 pp. 20-27
- cats, drug therapy, mast cells, neoplasms, retrospective studies
- BACKGROUND: Mast cell tumors (MCT) are common splenic tumors in cats, but there is limited information on treatment outcomes of cats with this disease. MATERIALS AND METHODS: This retrospective study evaluated treatment outcomes in 64 cats with splenic MCT. Cats were categorized into the following treatment groups: splenectomy (A, n = 20); splenectomy with chemotherapy (B, n = 20); chemotherapy alone (C, n = 15); or supportive care (D, n = 9). RESULTS: Median tumor specific survival (MTSS) was: 856, 853, 244, 365 days for groups A, B, C, and D, respectively. The MTSS was not significantly different between the 4 groups. However, comparing cats that had splenectomy (A and B) versus those that did not (C and D), the MTSS was 856 and 342 days, respectively (p=0.008). None of the prognostic factors analyzed significantly influenced survival. CONCLUSION: Splenectomy (+/‐ chemotherapy) significantly prolongs survival in cats with mast cell tumors. The role of chemotherapy remains unknown.